GILD:NASDAQ
Gilead Sciences, Inc
$127.88
arrow_upward
+3.26%(+4.04) 1D
$127.46
arrow_downward
-0.33% (-0.42)bedtimeAfter hours
Closed: Jun 26, 4:00:02 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
$125.25
High
$128.70
Low
$125.00
Mkt. cap
158.77B
Avg. vol.
8.02M
Volume
19.91M
Dividend
2.56%
Quarterly dividend
$0.82
Ex-dividend date
Jun 15, 2026
P/E ratio
17.40
52-wk high
$157.29
52-wk low
$106.84
EPS
$7.35
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
Open
$125.25
High
$128.70
Low
$125.00
Mkt. cap
158.77B
Avg. vol.
8.02M
Volume
19.91M
Dividend
2.56%
Quarterly dividend
$0.82
Ex-dividend date
Jun 15, 2026
P/E ratio
17.40
52-wk high
$157.29
52-wk low
$106.84
EPS
$7.35
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
News stories
From sources across the web
Ad-hoc-news.de
·
59 minutes ago
Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval
Yahoo Finance
·
6 hours ago
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Yahoo Finance
·
7 hours ago
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
Simply Wall Street
·
9 hours ago
Gilead (GILD) Wins FDA Approval For Trodelvy In First Line Triple Negative Breast Cancer
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
AI content may include mistakes. Learn more